Verastem, Inc.
Verastem, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for cancer. Its business centers on oncology drug candidates and approved products, with development, manufacturing, and commercialization activities conducted through third-party partners.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaApproved cancer treatment sold in the U.S. for a specific oncology indication.
Drug candidates in development for additional oncology indications and future approvals.
Activities tied to approval, launch, market access, and post-approval support.
Asiakkaat
Verastem’s direct customers are healthcare providers, hospitals, oncology practices, and specialty pharmacies that prescribe or dispense its cancer therapies. Indirectly, access depends on payors and government reimbursement programs, since coverage and rebate terms influence whether patients can obtain treatment. The company also relies on clinical investigators and research institutions during development of its pipeline.
Oncologists and cancer centers that prescribe AVMAPKI FAKZYNJA CO-PACK for eligible patients.
Dispense the product and manage patient access, fulfillment, and distribution.
Medicaid, 340B, VA/FSS, and private payors that determine reimbursement and net access.
Hospitals, investigators, and CRO-supported sites that run trials for pipeline candidates.
Strategia
Verastem’s strategy is centered on building a commercial oncology franchise around AVMAPKI FAKZYNJA CO-PACK while advancing additional product candidates through clinical development. The company also focuses on securing reimbursement, maintaining supply through third-party manufacturers, and expanding the evidence base needed for broader adoption and future approvals.
The company’s near-term business depends heavily on uptake of its approved oncology product.
Additional approvals are needed to diversify the product base and extend the franchise.
Third-party manufacturing is essential to both commercial supply and clinical development.
Maantiede
Verastem is headquartered in the United States and its commercial focus is primarily the U.S. market. The company also faces foreign-market pricing and reimbursement dynamics typical of global pharmaceutical development, but the disclosed commercial emphasis is domestic. Its operating model depends on third-party manufacturers and research partners, which can be located outside the company’s headquarters.
Riskit
Verastem is exposed to concentration risk because its business depends heavily on the commercial success of a single approved product and on future pipeline execution. The company also faces typical biotech risks around clinical trial failure, regulatory delays, third-party manufacturing dependence, reimbursement pressure, and financing needs.
- Dependence on AVMAPKI FAKZYNJA CO-PACKVaikutus: KorkeaTodennäköisyys: Kohtalainen
A large share of the company’s commercial prospects depends on one approved oncology product.
Kohdistuu: U.S. commercial sales
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Pipeline candidates may not show sufficient efficacy or safety to gain approval.
Kohdistuu: Product candidates in development
- Third-party manufacturing dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company has no manufacturing facilities and relies on external suppliers for supply.
Kohdistuu: Commercial and clinical supply
- Financing and debt servicing riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Debt obligations and potential acceleration could constrain operations and development spending.
Kohdistuu: Note Purchase Agreement and related indebtedness
- Reimbursement and pricing pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Coverage, rebates, and government pricing programs can reduce net revenue and access.
Kohdistuu - Regulatory and advertising enforcementVaikutus: KeskitasoTodennäköisyys: Kohtalainen
FDA and other agencies can impose requirements, warnings, or launch restrictions.
Kohdistuu: Commercial promotion and labeling
Kirjanpito
Harkinnanvaraiset erätPharmaceutical sales are recorded net of rebates, discounts, and chargebacks, which can materially change reported revenue.
Vaikutus: Net product revenue
Medicaid, 340B, and VA/FSS obligations require estimates and periodic true-ups.
Vaikutus: Accrued rebates and revenue reserves
Management must estimate future returns and reimbursement-related deductions based on limited launch history.
Vaikutus: Revenue and liabilities
Financing arrangements and revenue-sharing obligations affect balance sheet presentation and future cash flows.
Vaikutus: Interest expense, liabilities, and net revenue
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Immunome Inc.
IMNM · Pharmaceutical Preparations
Cogent Biosciences, Inc.
COGT · Pharmaceutical Preparations
Veraxa Biotech AG - Post de-SPAC
VRXA · Pharmaceutical Preparations
Veraxa Biotech AG is a Switzerland-based biotechnology company focused on discovering and developing next-generation antibody-based cancer therapeutics.
Upstream Bio, Inc.
UPB · Pharmaceutical Preparations
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
Päivitetty: 24.9.2026